Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 32 articles:
HTML format
Text format



Single Articles


    May 2017
  1. HIDA T, Nokihara H, Kondo M, Kim YH, et al
    Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Lancet. 2017 May 10. pii: S0140-6736(17)30565.
    PubMed     Text format     Abstract available


  2. GAINOR JF, Shaw AT
    J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer.
    Lancet. 2017 May 10. pii: S0140-6736(17)31074.
    PubMed     Text format    


    April 2017
  3. LANGLEY RE, Nankivell M, Barton R, Faivre-Finn C, et al
    Whole brain radiotherapy for non-small cell lung cancer - Authors' reply.
    Lancet. 2017;389:1395-1396.
    PubMed     Text format    


  4. ZHU J, Kang M, Fan X
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1395.
    PubMed     Text format    


  5. CAGNEY DN, Alexander BM, Aizer AA
    Whole brain radiotherapy for non-small cell lung cancer.
    Lancet. 2017;389:1394-1395.
    PubMed     Text format    


    January 2017
  6. SORIA JC, Tan DS, Chiari R, Wu YL, et al
    First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30123.
    PubMed     Text format     Abstract available


  7. SOLOMON B
    First-line treatment options for ALK-rearranged lung cancer.
    Lancet. 2017 Jan 23. pii: S0140-6736(17)30124.
    PubMed     Text format    


    December 2016
  8. LEDUC C, Quoix E
    Programmed death of chemotherapy in non-small-cell lung cancer?
    Lancet. 2016 Dec 12. pii: S0140-6736(16)32535.
    PubMed     Text format    


  9. RITTMEYER A, Barlesi F, Waterkamp D, Park K, et al
    Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
    Lancet. 2016 Dec 12. pii: S0140-6736(16)32517.
    PubMed     Text format     Abstract available


    October 2016
  10. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available


  11. ZHANG L, Huang Y, Hong S, Yang Y, et al
    Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
    Lancet. 2016;388:1883-1892.
    PubMed     Text format     Abstract available


    September 2016
  12. SCHILDGEN V, Schildgen O
    Routine molecular profiling of patients with NSCLC.
    Lancet. 2016;388:1054.
    PubMed     Text format    


  13. HIRSCH FR, Suda K, Wiens J, Bunn PA Jr, et al
    New and emerging targeted treatments in advanced non-small-cell lung cancer.
    Lancet. 2016;388:1012-24.
    PubMed     Text format     Abstract available


  14. HILEY CT, Le Quesne J, Santis G, Sharpe R, et al
    Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.
    Lancet. 2016;388:1002-11.
    PubMed     Text format     Abstract available


  15. MULVENNA P, Nankivell M, Barton R, Faivre-Finn C, et al
    Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiori
    Lancet. 2016 Sep 2. pii: S0140-6736(16)30825.
    PubMed     Text format     Abstract available


    August 2016
  16. HIRSCH FR, Scagliotti GV, Mulshine JL, Kwon R, et al
    Lung cancer: current therapies and new targeted treatments.
    Lancet. 2016 Aug 26. pii: S0140-6736(16)30958.
    PubMed     Text format     Abstract available


  17. THE LANCET
    Lung cancer: despite advances, prevention is still best.
    Lancet. 2016;388:533.
    PubMed     Text format    


    July 2016
  18. YAO JC, Voi M, Rouyrre N, Singh S, et al
    Everolimus in ileum neuroendocrine tumours - Authors' reply.
    Lancet. 2016;388:236-7.
    PubMed     Text format    


  19. WALTER T, Lombard-Bohas C
    Everolimus in ileum neuroendocrine tumours.
    Lancet. 2016;388:236.
    PubMed     Text format    


    May 2016
  20. RUSSELL P, Floridis J
    Hypertrichosis lanuginosa acquisita: a rare dermatological disorder.
    Lancet. 2016;387:2035.
    PubMed     Text format    


    April 2016
  21. HORNLUND A
    Clarification regarding ethical review of Paolo Macchiarini's research.
    Lancet. 2016;387:1816.
    PubMed     Text format    



  22. Expression of concern--Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study.
    Lancet. 2016;387:1359.
    PubMed     Text format    


    March 2016
  23. SMIT EF, van den Heuvel MM
    PD-L1 in non-small-cell lung cancer: the third target for immunotherapy.
    Lancet. 2016 Mar 10. pii: S0140-6736(16)00700.
    PubMed     Text format    


  24. FEHRENBACHER L, Spira A, Ballinger M, Kowanetz M, et al
    Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
    Lancet. 2016 Mar 9. pii: S0140-6736(16)00587.
    PubMed     Text format     Abstract available


  25. CLAESSON-WELSH L, Hansson GK
    Tracheobronchial transplantation: The Royal Swedish Academy of Sciences' concerns.
    Lancet. 2016;387:942.
    PubMed     Text format    


  26. YAO JC, Fazio N, Singh S, Buzzoni R, et al
    Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
    Lancet. 2016;387:968-77.
    PubMed     Text format     Abstract available


  27. OBERG K
    Universal everolimus for malignant neuroendocrine tumours?
    Lancet. 2016;387:924-6.
    PubMed     Text format    


    January 2016
  28. MACCHIARINI P
    Tracheobronchial transplantation.
    Lancet. 2016;387:339.
    PubMed     Text format    


  29. ROSELL R, Karachaliou N
    Large-scale screening for somatic mutations in lung cancer.
    Lancet. 2016 Jan 14. pii: S0140-6736(15)01125.
    PubMed     Text format    


  30. BARLESI F, Mazieres J, Merlio JP, Debieuvre D, et al
    Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT).
    Lancet. 2016 Jan 14. pii: S0140-6736(16)00004.
    PubMed     Text format     Abstract available


    December 2015
  31. MOK TS, Loong HH
    Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
    Lancet. 2015 Dec 18. pii: S0140-6736(15)01308.
    PubMed     Text format    


  32. HERBST RS, Baas P, Kim DW, Felip E, et al
    Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Lancet. 2015 Dec 18. pii: S0140-6736(15)01281.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: